Jakinus
Prescription
JAK Inhibitor
Tofacitinib Tablets
Manufacturer: Sun Pharma
Description
Jakinus is Sun Pharma's branded tofacitinib — an oral JAK1/JAK3 inhibitor used off-label in dermatology for alopecia areata, vitiligo, and refractory atopic dermatitis. Represents the new era of targeted small-molecule therapy in dermatology.
Active Compounds
No tracked compounds
Indications
- Alopecia areata (moderate-to-severe)
- Vitiligo (off-label)
- Refractory atopic dermatitis (off-label)
- Psoriatic arthritis
Dosage
5mg twice daily. Response in alopecia areata typically seen in 3–6 months.
Formulations
Full Ingredient List
- Tofacitinib Citrate
- Microcrystalline Cellulose
- Lactose Monohydrate
- Croscarmellose Sodium
- Magnesium Stearate
- Hypromellose
- Titanium Dioxide
Side Effects
- Increased infection risk (including herpes zoster)
- Elevated cholesterol
- Cytopenias
- GI perforation (rare)
- Increased cardiovascular and malignancy risk (FDA warning)
Warnings
- FDA black box warning for cardiovascular events, malignancy, and thrombosis
- Screen for infections and tuberculosis before starting
- Regular CBC, LFT, and lipid monitoring
- Avoid live vaccines
- Increased herpes zoster risk — consider vaccination